Ocana A - Search Results

1

Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Saleh RR, Scott JL, Meti N, Perlon D, Fazelzad R, Ocana A, Amir E. Saleh RR, et al. Among authors: ocana a. Mol Diagn Ther. 2022 Mar;26(2):153-168. doi: 10.1007/s40291-022-00576-4. Epub 2022 Feb 1. Mol Diagn Ther. 2022. PMID: 35106739

2

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

Ocaña A, Amir E. Ocaña A, et al. Cancer Treat Rev. 2009 Dec;35(8):685-91. doi: 10.1016/j.ctrv.2009.08.001. Epub 2009 Sep 4. Cancer Treat Rev. 2009. PMID: 19733440 Review.

3

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Cancer Treat Rev. 2010. PMID: 20100635 Review.

4

Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.

Amir E, Ocaña A, Seruga B, Josse R, Clemons M. Amir E, et al. Among authors: ocana a. Nat Rev Clin Oncol. 2010 Apr;7(4):187-8. doi: 10.1038/nrclinonc.2010.19. Nat Rev Clin Oncol. 2010. PMID: 20354540

5

Targeting DNA repair in breast cancer: a clinical and translational update.

Amir E, Seruga B, Serrano R, Ocana A. Amir E, et al. Among authors: ocana a. Cancer Treat Rev. 2010 Nov;36(7):557-65. doi: 10.1016/j.ctrv.2010.03.006. Epub 2010 Apr 10. Cancer Treat Rev. 2010. PMID: 20385443 Review.

6

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

Ocaña A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Ocaña A, et al. J Clin Oncol. 2011 Jan 20;29(3):254-6. doi: 10.1200/JCO.2010.32.0275. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149670 No abstract available.

7

Clinical research: show us the data.

Ocana A, Amir E, Seruga B. Ocana A, et al. J Clin Oncol. 2011 Mar 20;29(9):1099-100. doi: 10.1200/JCO.2010.33.1462. Epub 2011 Feb 14. J Clin Oncol. 2011. PMID: 21321295 No abstract available.

8

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.

Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Amir E, et al. Among authors: ocana a. J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606435

9

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Amir E, et al. Among authors: ocana a. J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. J Natl Cancer Inst. 2011. PMID: 21743022 Review.

10

Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?

Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Amir E, et al. Among authors: ocana a. Eur J Cancer. 2012 Feb;48(3):385-8. doi: 10.1016/j.ejca.2011.10.028. Epub 2011 Nov 22. Eur J Cancer. 2012. PMID: 22115991

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

276 results

Search Page